Compugen FDA Approval for COM902
- Compugen Announces FDA Clearance of IND Application for COM902
- Phase 1 clinical study in patients with advanced malignancies expected to begin in early 2020
- Clinical development of COM902 will enable testing the combination treatment with COM701, Compugen’s anti-PVRIG inhibitor
Compugen (CGEN) is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy.
In the NEWS
The U.S. Food and Drug Administration (FDA) has cleared Compugen’s investigational new drug (IND) application for COM902 its immuno-oncology therapeutic antibody targeting TIGIT in patients with advanced cancers.
With the FDA approval of the IND Compugen decided to initiate a Phase 1 clinical trial in patients with advanced malignancies for whom the standard of care therapies are currently ineffective. The clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of COM902. The study is planned to be conducted at multiple centers in the United States and site selection activities are currently underway.
The trial is expected to start early next year.